|Trade names||Alamast, Alegysal, others|
|Other names||Pemirolast potassium|
|Drug class||Mast cell stabilizer|
|Main uses||Allergic conjunctivitis|
|Side effects||Headache, runny nose|
|By mouth, eye drop|
|Chemical and physical data|
|Molar mass||228.215 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
It may be used as 1 to 2 drops up to 4 times per day.
It has also been studied for the treatment of asthma. Pemirolast has appeared as a possible candidate for SARS-CoV-2 (COVID-19) spike protein disruption and interference. Such results were ascertained by molecular dynamics calculations executed on the Summit supercomputer. By simulating compounds with FDA or similar regulatory approval, the authors found 4 interfacial molecules that could potentially disrupt the SARS-CoV-2 interface with ACE-2 receptors, suggesting that such small molecules could mitigate SARS-CoV-2 infection. The 4 candidate interfacial molecules included pemirolast, isoniazid pyruvate, nitrofurantoin, and eriodictyol.
- "Pemirolast Monograph for Professionals". Drugs.com. Retrieved 27 October 2021.
- "Pemirolast ophthalmic (Alamast) Use During Pregnancy". Drugs.com. 2 September 2020. Retrieved 13 September 2020.
- "Pemirolast ophthalmic (Alamast) Use During Pregnancy". Drugs.com. Retrieved 27 October 2021.
- "Pemirolast Prices and Pemirolast Coupons - GoodRx". GoodRx. Retrieved 27 October 2021.
- Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis". Cochrane Database Syst Rev. 6 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMID 26028608.CS1 maint: uses authors parameter (link)
- Smith, MD, Smith JC (April 2020). "Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface". Preprint: 1–28.
- "Pemirolast Potassium". Drug Information Portal. U.S. National Library of Medicine.